Blair William & CO Autolus Therapeutics PLC Transaction History

Blair William & CO

$33.4 Billion
Q3 2024

A detailed history of Blair William & CO transactions in Autolus Therapeutics PLC stock. As of the latest transaction made, Blair William & CO holds 14,932 shares of AUTL stock, worth $35,090. This represents 0.0% of its overall portfolio holdings.

Number of Shares

14,932

Previous 18,794 20.55%

Holding current value

$35,090

Previous $65,000 16.92%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	SELL	$3.38 - $4.69 $13,053 - $18,112	-3,862 Reduced 20.55%	14,932 $54,000
Q2 2024 Aug 12, 2024	SELL	$3.33 - $5.68 $1,042 - $1,777	-313 Reduced 1.64%	18,794 $65,000
Q1 2024 May 09, 2024	SELL	$5.39 - $7.29 $43,120 - $58,320	-8,000 Reduced 29.51%	19,107 $121,000
Q4 2023 Feb 12, 2024	BUY	$2.13 - $6.63 $29,820 - $92,820	14,000 Added 106.81%	27,107 $174,000
Q1 2023 May 12, 2023	SELL	$1.75 - $2.25 $409 - $526	-234 Reduced 1.75%	13,107 $24,000
Q1 2022 May 13, 2022	BUY	$3.52 - $5.46 $7,645 - $11,859	2,172 Added 19.45%	13,341 $56,000
Q4 2021 Feb 14, 2022	BUY	$5.1 - $7.0 $56,961 - $78,183	11,169 New	11,169 $58,000
Q2 2019 Aug 13, 2019	SELL	$15.1 - $31.25 $181,200 - $375,000	-12,000 Closed	0 $0
Q1 2019 May 14, 2019	SELL	$24.38 - $34.71 $234,048 - $333,216	-9,600 Reduced 44.44%	12,000 $378,000
Q4 2018 Feb 14, 2019	SELL	$24.21 - $48.01 $222,732 - $441,692	-9,200 Reduced 29.87%	21,600 $709,000
Q3 2018 Nov 13, 2018	BUY	$20.86 - $33.33 $458,920 - $733,260	22,000 Added 250.0%	30,800 $945,000
Q2 2018 Aug 13, 2018	BUY	$25.0 - $27.75 $220,000 - $244,200	8,800 New	8,800 $236,000

Others Institutions Holding AUTL

# of Institutions

104

Shares Held

163M

Call Options Held

2.8K

Put Options Held

13.4K

View Full List

About Autolus Therapeutics plc

Ticker AUTL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 90,909,800
Market Cap $214M
Description
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...

More about AUTL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Blair William & CO, based on Form 13F filings with the SEC.

News

Stay updated on Blair William & CO with notifications on news.

Account